Genentech is committed to helping people access the medicines they are prescribed and will be offering comprehensive services for people prescribed Susvimo to help minimize barriers to access and ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

Credit: Genentech. Susvimo is indicated for intravitreal use via the Susvimo ocular implant. For patients with diabetic retinopathy, refills of Susvimo are administered every 36 weeks ...

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative ...

– Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months – – Susvimo’s innovative technology via ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for ...